Minnesota House File 4852: Formulary Committee members with a potential conflict of interest permitted to participate in committee communications and discussions, commissioner of human services required to develop a public comment process for recommendations, and committee required to seek expertise from the Minnesota Rare Disease Advisory Council.

Minnesota · 2025-2026 Regular Session

What it does

Formulary Committee members with a potential conflict of interest permitted to participate in committee communications and discussions, commissioner of human services required to develop a public comment process for recommendations, and committee required to seek expertise from the Minnesota Rare Disease Advisory Council.

Latest action

Introduction and first reading, referred to Health Finance and Policy (2026-04-07)

See how HF 4852 affects you on CapitolKey

Browse more bills · CapitolKey home